How Are Cell and Gene Therapies Manufactured at Commercial Scale?

Cell and gene therapy manufacturing produces either a viral vector carrying a therapeutic gene or living cells engineered with one, under good manufacturing practice controls. FDA's January 2020 CMC guidance defines the IND baseline: enough information to assure safety, identity, quality, purity, and strength. Dozens of therapies are now licensed.

What are the two basic manufacturing models?

The industry splits into autologous and allogeneic models. Autologous therapy means the product is manufactured from the patient's own cells: cells are collected, shipped to a manufacturing site, engineered, expanded, tested, and shipped back for infusion as a single patient-specific batch. Allogeneic therapy uses donor cells engineered as one large batch intended for many patients, which moves manufacturing closer to conventional biologic drug production.

The autologous model dominates the licensed CAR-T class, and it is logistically punishing. Every patient is a separate manufacturing run with its own release testing, its own chain of identity, and its own failure risk. Vein-to-vein times of weeks are routine. Allogeneic batches carry immunology questions instead, because a donor-derived product can be rejected by the recipient's immune system, and several allogeneic programs have added gene edits precisely to reduce that risk. The trade is manufacturing scale against immune compatibility.

How is the viral vector itself made?

Most gene therapies and all engineered cell therapies depend on a viral vector, commonly AAV or a lentiviral vector, to deliver genetic material. Vector manufacturing uses producer cell lines or transient transfection in cell culture, followed by purification and fill. The output must be characterized for vector genome titer, empty-to-full capsid ratio for AAV, residual host-cell impurities, and potency. FDA's CMC guidance for human gene therapy INDs states that it informs sponsors how to provide sufficient CMC information required to assure product safety, identity, quality, purity, and strength, including potency, under 21 CFR 312.23.

Vector capacity has repeatedly been the industry's bottleneck, because vector processes scale poorly and demand from commercial gene therapies plus clinical programs exceeds installed capacity. That is why vector supply agreements are signed years ahead of approvals, and why several license holders invested in internal vector plants rather than relying on contract capacity alone.

What does the cell-processing chain look like for an autologous product?

The autologous chain is a sequence of tightly timed steps, each with its own controls.

1. Apheresis collects the patient's cells at the treatment center.
2. Chain-of-custody shipping moves the starting material to the manufacturing site.
3. Activation, transduction with the viral vector, and expansion produce the engineered cell population.
4. Formulation and cryopreservation prepare the final product.
5. Release testing covers identity, purity, potency, and sterility before the product is shipped back.
6. Infusion at the treatment center, often after lymphodepleting conditioning.

How does FDA evaluate the manufacturing package?

The review is documentary and continuing. At IND, the CMC guidance expectations apply; at licensure, the biologics license application must show a validated, controlled process with comparability data across process changes. FDA's list of approved cellular and gene therapy products shows what has cleared that bar: CAR-T products such as Carvykti and Breyanzi, AAV gene therapies such as Hemgenix and Elevidys, and the CRISPR-edited Casgevy, each licensed with its own manufacturing controls. The list is maintained by CBER's Office of Therapeutic Products.

The economics follow from the design choices. An autologous product's cost scales with patient count rather than batch size, which is why manufacturing innovation in the field targets closed, automated systems that shrink labor and cleanroom footprint per patient. The gap between a successful pivotal trial and a scalable commercial process is where much of the industry's engineering effort is currently spent, and the therapies that have crossed to approval are the ones whose processes were industrialized rather than merely replicated.

How do AAV and lentiviral vectors differ as platforms?

AAV and lentiviral vectors are the two workhorse delivery systems, and they impose different manufacturing profiles. AAV is a non-enveloped parvovirus used mainly for in vivo gene addition: it delivers a payload to tissues such as liver, muscle, or retina, and its production is dominated by either helper-cell transient transfection or producer cell lines. Lentiviral vectors are enveloped retroviruses used to permanently integrate a transgene into the target cell's genome, which is why ex vivo engineered cell therapies are built on them.

The manufacturing consequences run in opposite directions. AAV campaigns chase titer, empty capsid reduction, and potency assays tied to transgene expression in whole-animal or cell models. Lentiviral campaigns chase functional titer, residual plasmid and host-cell impurities, and the infectivity of a fragile enveloped particle, which limits cold-chain tolerance and holding times. Neither process scales the way monoclonal antibody culture does.

The licensed portfolio reflects the split. The AAV branch includes products such as Hemgenix and Elevidys, while the lentiviral branch includes the CAR-T and Lyfgenia families, per FDA's approved products list. Process development for each platform is therefore a distinct discipline, and capacity for one does not transfer automatically to the other.

What is release testing, and why does it pace the timeline?

Release testing is the set of assays every batch must pass before use, and for autologous therapies it is the critical path. A CAR-T lot undergoes identity testing to confirm the engineered cells are the patient's own, purity and residual impurity testing, cell viability and count, sterility and endotoxin, and a potency assay that measures the product's intended biological effect. Potency is typically the slow assay, and it is the one regulators scrutinize hardest because it defines whether the product can work.

Sterility adds a scheduling wrinkle that no engineering fix has removed: conventional sterility methods carry incubation days. Until rapid microbiological methods are accepted for specific products, the release clock includes that wait, which is why vein-to-vein times are measured in weeks even when manufacturing itself takes only a fraction of that.

The testing burden explains the industry's automation push. Closed, automated cell-processing systems reduce operator variance and cleanroom hours, but the release panel remains the bottleneck. Programs that shorten it, through validated rapid assays and platform analytical methods, cut both cost and time per patient.

How do the two models compare as businesses?

The economic contrast between autologous and allogeneic manufacturing is stark enough to summarize in a table.

Neither model wins outright. Autologal programs carry the treatments that work today in refractory blood cancers; allogeneic programs promise the cost curve that would widen access. FDA's CMC framework, from the January 2020 IND guidance through licensure expectations, is written to accommodate both, which is why the same four CMC headings appear in files of either kind.

Capacity planning closes the picture. Vector suites, cell-processing cleanrooms, and cryogenic logistics each have long lead times, and licensure can convert a clinical-scale process into a commercial bottleneck overnight. The sponsors that scale cleanly are the ones that treated manufacturing as part of the product from the first IND, which is precisely the posture FDA's CMC framework rewards.